[(2S,3R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: [(2S,3R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
• 化学式: C₁₀H₁₄N₅O₇P
• 分子量: 347.22
• InChiKey: LTFMZDNNPPEQNG-NGJCXOISSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  182
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3066125A2

  公开（公告）日：2016-09-14
• COMBINATION THERAPIES WITH EHMT2 INHIBITORS
  申请人：Epizyme Inc

  公开号：EP3612181A1

  公开（公告）日：2020-02-26
• [EN] PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS<br/>[FR] COMBINAISONS PHARMACEUTIQUES COMPRENANT DES ANTICORPS CD33 ET DES AGENTS DE DÉMÉTHYLATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015067570A2

  公开（公告）日：2015-05-14

  The present invention relates to pharmaceutical combinations CD33 antibodies and de-methylating agents for use in treating diseases like MDS and cancer, especially AML.
• [EN] COMBINATION THERAPIES WITH EHMT2 INHIBITORS<br/>[FR] THÉRAPIES D'ASSOCIATION AVEC DES INHIBITEURS D'EHMT2
  申请人：EPIZYME INC

  公开号：WO2018195450A1

  公开（公告）日：2018-10-25

  The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compoundsor combinations for research or other non-therapeutic purposes.